Related Experiment Video
Updated: Aug 17, 2025

09:36
Modified Heterotopic Hindlimb Osteomyocutaneous Flap Model in the Rat for Translational Vascularized Composite Allotransplantation Research
Published on: April 26, 2019
5.9K
Reciprocal Donor-Recipient Strain Combinations Present Different Vascularized Composite Allotransplantation Outcomes
Hui-Yun Cheng1, Chih-Fan Lin1, Madonna Rica Anggelia1,2
1From the Center for Vascularized Composite Allotransplantation.
Plastic and Reconstructive Surgery
|December 12, 2022
Summary
Vascularized composite allotransplantation (VCA) outcomes vary by donor-recipient pairs and immunosuppression. Maintaining donor chimerism for 30 days post-surgery improves VCA survival, necessitating tailored regimens.
Area of Science:
- Immunology
- Transplantation Biology
- Regenerative Medicine
Background:
- Vascularized composite allotransplantation (VCA) research requires generalized models and immunosuppression regimens applicable across diverse donor-recipient combinations.
- This study evaluates VCA outcomes in reciprocal rodent donor-recipient models.
Purpose of the Study:
- To assess the efficacy of different immunosuppression regimens in reciprocal rodent VCA models.
- To identify factors influencing VCA success in varied donor-recipient combinations.
Main Methods:
- Rats (Lewis and Brown Norway) and mice (Balb/C and C57BL/6) underwent VCA using specific immunosuppression protocols.
- Immunosuppression regimens included antilymphocyte serum/cyclosporine/adipose-derived stem cells in rats and co-stimulatory blockade/rapamycin in mice.
Main Results:
- VCA outcomes and response to immunosuppression differed between reciprocal donor-recipient pairs in both rats and mice.
- Modifications to the surgical site and immunosuppression duration (cyclosporine) improved outcomes in BN rats.
- Peripheral chimerism at postoperative day 30 correlated with VCA tolerance and long-term allograft survival.
Conclusions:
- Reciprocal donor-recipient combinations significantly impact VCA outcomes and immunosuppression effectiveness.
- Sustained donor chimerism for at least 1 month post-VCA is crucial for long-term allograft survival.
- Tailoring VCA models and immunosuppression regimens to specific recipient backgrounds is recommended for optimal results.

